



This is a repository copy of *Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by the American Diabetes Association/European Association for the study of diabetes.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/154319/>

Version: Accepted Version

Article:

Heller, S.R. orcid.org/0000-0002-2425-9565, Buse, J.B., Ratner, R. et al. (5 more authors) (2019) Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by the American Diabetes Association/European Association for the study of diabetes. *Diabetes Care*. dc182361. ISSN 0149-5992

<https://doi.org/10.2337/dc18-2361>

© 2019 by the American Diabetes Association. This is an author-created, uncopyedited electronic version of an article accepted for publication in *Diabetes Care*. The American Diabetes Association (ADA), publisher of *Diabetes Care*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of/has been published in *Diabetes Care* in print and online at <https://doi.org/10.2337/dc18-2361>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by American Diabetes Association/European Association for the Study of Diabetes

Short running title: IHSG hypoglycemia definition in clinical trials

Simon R. Heller, M.D.¹, John B. Buse, M.D.², Robert Ratner, M.D.³, Elizabeth Seaquist, M.D.⁴, Lars Bardtrum, M.Sc.⁵, Charlotte Thim Hansen, M.D.⁵, Deniz Tutkunkardas, M.D.⁵, and Alan C. Moses, M.D.^{6,7}

1. Academic Unit of Diabetes, Oncology and Metabolism, University of Sheffield, Sheffield, UK
2. University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
3. Division of Endocrinology and Metabolism, Georgetown University Medical School, Washington, DC, USA
4. Department of Medicine, University of Minnesota, Minneapolis, USA
5. Novo Nordisk A/S, Søborg, Denmark
6. Novo Nordisk Inc., Plainsboro, NJ, USA*
7. Independent consultant, Portsmouth, NH, USA

*At the time of the trial.

Corresponding Author: Simon Heller, Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.

Email: s.heller@sheffield.ac.uk; Tel: +44 114 215 9009

Main text word count: 2298 (maximum 4000)

Number of figures and tables: 4 (maximum 4)

Journal: Diabetes Care

Article type: Original Article

Abstract

Objective: The purpose of this study was to determine if the International Hypoglycemia Study Group (IHSG) Level 2 low glucose definition can identify clinically relevant hypoglycemia in clinical trials and offer value as an endpoint for future trials.

Research design and methods: A post hoc analysis of the SWITCH (SWITCH 1: n=501, type 1 diabetes; SWITCH 2: n=721, type 2 diabetes) and DEVOTE (n=7637, type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials were randomized to either insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100). In the main analysis, the following definitions were compared: 1) ADA 2005 (plasma glucose [PG] confirmed ≤ 3.9 mmol/L with symptoms); 2) IHSG Level 2 (glucose confirmed < 3.0 mmol/L).

Results: In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated increasing differences between treatments with decreasing PG levels until 3.0 mmol/L, following which no additional treatment differences were observed. In SWITCH 2, the IHSG Level 2 definition produced a rate ratio that was lower than the ADA 2005 definition. Similar results were observed for the SWITCH 1 trial.

Conclusions: The IHSG Level 2 definition was validated in a series of clinical trials, demonstrating its ability to discriminate between basal insulins. This definition is therefore recommended to be uniformly adopted by regulatory bodies and used in future clinical trials.

Currently, the definition of hypoglycemia differs between regulatory bodies as well as across clinical trials (1–7). For example, hypoglycemia can be defined with or without a plasma glucose (PG) value, with or without the presence of symptoms, with a requirement for medical assistance (e.g. emergency medical services or hospitalization) or by different levels of cognitive dysfunction. This variation in hypoglycemia definitions has limited the diabetes community's ability to compare the safety and tolerability of therapies across clinical trials, despite some studies investigating a range of hypoglycemia definitions, such as the EDITION trials (7).

As a result, the International Hypoglycemia Study Group (IHSG), a group of clinicians formed to promote greater understanding of the clinical impact of hypoglycemia, recently proposed a revised classification of low glucose in diabetes (8). The IHSG proposed three definition levels be adopted universally – Level 1: glucose ≤ 3.9 mmol/L; Level 2: glucose < 3.0 mmol/L; Level 3: severe events requiring third party intervention independent of a defined glucose value (9). Of these three, the IHSG proposed that the Level 2 definition should be added to current classifications as a level sufficiently low to indicate clinically significant hypoglycemia. This proposal has subsequently been accepted and adopted by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) and other organizations including, importantly, the European Medicines Agency (EMA) (8,10,11). The IHSG Level 2 definition was based on evidence derived from experimental pathophysiological studies and small clinical trials, but has not been applied to larger-scale clinical trial data involving patients with type 2 diabetes (8). The aim of the present study was to validate the IHSG Level 2 definition by applying it to a series of clinical trials in patients with type 1 or type 2 diabetes, investigate the clinical relevance of hypoglycemia defined with a low

glucose cut-off, and demonstrate the utility of the IHSG Level 2 definition in the conduct of future clinical trials of basal insulins.

Research design and methods

To apply the IHSG low glucose definitions, data from three double-blind, basal insulin comparator trials (SWITCH trials [ClinicalTrials.gov numbers NCT02030600 {SWITCH 2, type 2 diabetes} and NCT02034513 {SWITCH 1, type 1 diabetes} (12,13)]; DEVOTE cardiovascular outcomes trial [ClinicalTrials.gov number NCT01959529 {type 2 diabetes} (14,15)]) were utilized. These trials were all conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice Guideline (16,17), and detailed accounts of their trial designs, methods and primary results have been published previously (12–15). A summary of these trials is included in **Supplementary Table 1**.

The purpose of this study was to apply the IHSG low glucose definitions to the SWITCH and DEVOTE trials. A summary of the definitions used in this analysis can be found in **Supplementary Table 2**. The IHSG considered glucose concentrations detected by self-/laboratory-measured plasma glucose or continuous glucose monitoring. Here we use the IHSG terminology of ‘glucose’ whether from capillary, venous, arterial or interstitial fluid sample measurements. Briefly, the IHSG Level 2 (confirmed events <3.0 mmol/L (8)) and IHSG Level 3 (events requiring third-party assistance (8,9)) definitions were applied to the trial data. For additional comparison, the ADA 2005 definition (a PG of ≤ 3.9 mmol/L with symptoms (18)) and the Novo Nordisk definition (a PG of <3.1 mmol/L with symptoms plus severe events [events requiring third-party assistance] (12,13)) were also included. Due to the DEVOTE trial design, only the IHSG Level 3 hypoglycemia definition was assessed in this trial.

In view of the double-blind, cross-over design of the SWITCH trials and increasing attention on hypoglycemia as an important consideration in type 2 diabetes management, the focus of this analysis was on the SWITCH 2 (type 2 diabetes) trial results. Results from the SWITCH 1 (type 1 diabetes) trial can be found in the Supplementary appendix and the severe hypoglycemia (IHSG Level 3) results from DEVOTE are included in **Figure 4**.

Statistical analyses

Due to the cross-over design of the SWITCH trials, hypoglycemia was analyzed with a Poisson model with patients as a random effect comparing insulin degludec (degludec) with insulin glargine 100 units/mL (glargine U100). The DEVOTE trial analyzed hypoglycemia using a negative binomial-regression model comparing degludec with glargine U100.

The frequency of hypoglycemic events was assessed by PG levels within the range of 2.0–3.9 mmol/L on a pooled randomized treatment dataset. The hypoglycemia rate ratios (degludec versus glargine U100) were assessed by glucose levels within the same range. This range was selected to encompass the full extent of the ADA 2005 and IHSG Level 2 definitions while taking into consideration the low number of hypoglycemic events that occur below 2.0 mmol/L.

Results

In SWITCH 1 and 2, the rate of non-severe hypoglycemic events (both symptomatic and combined asymptomatic/symptomatic events) increased from 3.0 to 3.9 mmol/L with a greater number of events at PG levels approaching 3.9 mmol/L versus PG levels approaching 3.0 mmol/L (**Figure 1**). Similar rates of hypoglycemic events

were seen for the total treatment period and after 16 weeks of titration (the maintenance period) (**Figure 1 and Supplementary Figure S1**).

In SWITCH 1 and 2, the estimated rate ratios of hypoglycemic events comparing two basal insulins decreased with decreasing glucose cut-off levels until 3.0 mmol/L, indicating greater divergence between the basal insulins with respect to hypoglycemic risk (**Figure 2**). Thereafter, a plateau was reached and the differences between the two insulins did not increase any further. A similar result was seen for both the maintenance and total treatment periods (**Figure 2 and Supplementary Figure S2**). It is important to note that the confidence intervals widen at the lower glucose levels due to the fewer number of events as illustrated in **Figure 1 and Supplementary Figure S1**. This is reflected by the upper confidence intervals, which in SWITCH 2 cross the rate ratio of 1 at approximately 2.7 mmol/L and in SWITCH 1 at approximately 2.5 mmol/L (**Figure 2**). In addition, the differences between treatments in terms of reduction in hypoglycemia increased, represented by the lower estimated rate ratios at each glucose level, when asymptomatic events were excluded (**Figure 2**). Lastly, minimal differences in the rate ratios were observed between the 3.0 mmol/L and the 3.1 mmol/L cut-offs.

Figure 3 shows that symptoms were reported for 70–80% of non-severe hypoglycemic events with glucose levels <3.0 mmol/L while decreasing to approximately 40% for those events with glucose levels at 3.9 mmol/L.

In SWITCH 2, the IHSG Level 2 definition produced a rate ratio of 0.76 [0.67; 0.86]_{95% CI} for degludec versus glargine U100, which is in line with the point estimates utilizing the the pre-specified Novo Nordisk hypoglycemia definition (**Figure 4**). Compared with the ADA 2005 definition, the differences between the

insulins increased with the IHSG Level 2 and Novo Nordisk definitions although the rate ratios for the Novo Nordisk definition were lower, as this definition included confirmed symptomatic events only (**Figure 4**). Comparable results across the definitions were observed for the maintenance and total treatment periods.

In terms of severe hypoglycemia (IHSG Level 3), there was a similarly lower rate ratio of hypoglycemia with degludec versus glargine U100 for both treatment periods and also for the larger and longer trial, DEVOTE, where the confidence intervals were narrower due to the larger number of events (**Figure 4**). The rate ratios of hypoglycemic events for the SWITCH 1 trial can be seen in **Supplementary Figure S3**.

Conclusions

The results from this analysis provide external validation for the IHSG Level 2 definition by demonstrating that this definition could identify greater differences between two different basal insulins in patients with type 1 or type 2 diabetes compared with the ADA 2005 definition. The limited power to identify differences between two basal insulins recorded at blood glucose levels above 3.0 mmol/L supports the IHSG's recommendations that events between 3.0 and 3.9 mmol/L (Level 1), while serving as an alert value, do not necessarily need to be reported as the primary outcome in clinical trials. However, while the discriminatory power between treatments at glucose levels between 3.1 and 3.9 mmol/L is limited and arguably, less clinically relevant, it may be pertinent for these events still to be recorded, perhaps as secondary outcomes, given the importance to patients of needing to deal with such episodes. This would ensure that events most critical for the ongoing health of patients (<3.0 mmol/L) are recorded and allow for accurate

comparisons between treatments, while still recording those events at higher glucose levels (≥ 3.0 mmol/L). It seems likely, that our understanding of the consequences of particular glucose levels will evolve as more trials begin to include continuous glucose monitoring that can assess the full range of glucose levels over 24 hours.

An additional observation from this analysis was that the rate ratios of hypoglycemia change across a range of PG values. This highlights the need for the same glucose definitions to be used across clinical trials as different results can be obtained depending on the definition. Furthermore, applying the IHSG Level 2 definition did not change the previous conclusions from the SWITCH trials. Therefore, we acknowledge that while the differences between 3.0 and 3.1 mmol/L are negligible, as might be expected, our study supports the importance of the IHSG Level 2 definition (glucose < 3.0 mmol/L) for consistency across clinical trials.

Lastly, the requirement to identify symptoms associated with a hypoglycemic event is not essential to be able to differentiate between treatments, particularly since thresholds for symptoms can vary between individuals as well as within the same individual on different occasions. In the present analysis, the power to differentiate between basal insulins increased when only symptomatic events were included (Novo Nordisk definition). This is pertinent to the Food and Drug Administration (FDA) definition of hypoglycemia that currently stipulates that an event should be associated with symptoms and have a PG level < 3.9 mmol/L (19). However, asymptomatic events should not be overlooked; arguably they are more clinically relevant as they lead to cognitive impairment, reduced hypoglycemia awareness and are associated with cardiac arrhythmias (18,20–22). Therefore, we would argue that in future clinical trials, both events with and without symptoms are recorded, but with

the knowledge that excluding asymptomatic events may further highlight the differences between interventions, at least in the case of basal insulins.

Removing the confounding element of different hypoglycemia definitions will add power to future analyses of treatments across clinical trials. By also focusing on those events with a lower glucose, trials can highlight clinically important events while excluding events at higher glucose levels that may be less clinically relevant. The ADA, EASD and EMA have already taken the step to incorporate the IHSG definitions in their guidance documents (8,10,11). To ensure that clinicians are aligned globally we hope that the FDA and other regulatory bodies will consider incorporating these definitions in an updated guidance. It will also be important for pharmaceutical companies to take steps to align the definitions of hypoglycemia in their clinical trials. Furthermore, it could be pertinent for companies to analyze their data retrospectively with the IHSG Level 2 definition so that new meta-analyses across trials can be conducted.

The current analysis has a number of limitations. DEVOTE only collected severe hypoglycemic events (IHSG Level 3), thereby limiting comparisons with the other definitions used in this analysis. However, the point estimate for the relative risk was comparable to SWITCH 2 with narrower confidence intervals, emphasizing the increased statistical power of a trial with a larger number of events.

As shown in Figure 2, there was a smaller number of events at lower PG levels, reflected by the widening confidence intervals, thereby limiting the interpretation of these events. Thus, the choice of a clinically relevant hypoglycemic level to be used in clinical trials is a compromise between one which highlights the difference between two insulins while retaining sufficient power to demonstrate statistical

significance. This is clearly shown in SWITCH 2 (**Figure 2**) where the rate ratios fall to a minimum at PG levels of 2.9–3.0 mmol/L. At PG levels below this, the confidence intervals widen, so that at 2.7 mmol/L the rate ratio no longer achieves statistical significance. We would argue this justifies the choice of a glucose level below 3.0 mmol/L to be used in clinical trials. The differences observed between the two basal insulins in SWITCH 1 are less clear-cut, presumably due to the addition of bolus insulin that contributed to the total number of hypoglycemic events, but a PG level below 3.0 mmol/L appears to be a reasonable compromise.

Our analysis only extends to clinical trials investigating basal insulins as that was the focus of the comparisons in the trials analyzed. Therefore, the applicability of these findings to trials comparing other interventions is unknown. Lastly, these trials did not include data from continuous glucose monitoring, which is being increasingly adopted as a gold standard for hypoglycemia detection with its own recommendations for reporting (23).

This analysis also has a number of strengths including the double-blind trial design of the SWITCH and DEVOTE trials and the cross-over design of the SWITCH trials. Furthermore, in the SWITCH and DEVOTE trials, individuals with a prior history of multiple hypoglycemic events or severe hypoglycemia were not excluded, arguably making these trials and our analysis more relevant to patients seen in routine clinical practice. In addition, this analysis included a large number of patients across the SWITCH and DEVOTE trials as well as a high number of independently adjudicated severe hypoglycemic events (Level 3; SWITCH and DEVOTE), emphasizing the robustness of this analysis.

In conclusion, as the glucose threshold defining hypoglycemic events is decreased, fewer events occur. These events are more symptomatic and the discriminatory power between two basal insulins increases. Therefore, the results from this analysis provide empirical support, based on clinical trials with a double-blind design, for the adoption of the IHSG Level 2 definition by regulatory bodies and future clinical trials.

Author contributions:

Simon R. Heller, John B. Buse and Alan C. Moses conceived and designed the study, acquired, analyzed and interpreted the data and drafted and revised the manuscript. Robert Ratner, Elizabeth Seaquist, Charlotte Thim Hansen and Deniz Tutkunkardas analyzed and interpreted the data and drafted and revised the manuscript. Lars Bardtrum conceived and designed the study, acquired, analyzed and interpreted the data, performed statistical analyses and drafted and revised the manuscript.

Data sharing statement:

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of interests:

SH has served on speaker panels for Eli Lilly and Novo Nordisk, for which he has received remuneration. He has served on advisory panels or as a consultant for Zealand, UNEEG Medical, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi Aventis and Takeda for which his institution has received remuneration.

JBB's contracted consulting fees are paid to the University of North Carolina by Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, MannKind, NovaTarg, Novo Nordisk, Senseonics, vTv Therapeutics and Zafgen; grant support from Novo Nordisk, Sanofi and vTv Therapeutics. He is a consultant to Cirius Therapeutics Inc., CSL Behring, Neurimmune AG, and Whole Biome. He holds stock options in Mellitus Health, PhaseBio, Stability Health, and Whole Biome. He is supported by grants from the National Institutes of Health (UL1TR002489, U01DK098246, UC4DK108612 and U54DK118612), PCORI and ADA.

RR has served as a consultant to Novo Nordisk, Merck, Dexcom, Intarcia and Virta.

ES has served as a consultant for Eli Lilly, Zucara, Sanofi, MannKind, WebMD and 360 Consulting. She received grant funding from Eli Lilly and Locemia that went to her institution.

LB, CTH and DT are full-time employees of, and hold stock in, Novo Nordisk A/S. ACM was a full-time employee of Novo Nordisk until June 30, 2018. He currently serves as an independent consultant and holds shares in Novo Nordisk A/S.

Source of funding: These trials and this secondary analysis were funded by Novo Nordisk.

Role of the Funder/Sponsor: Novo Nordisk was involved in the design of this secondary analysis, provided logistical support, and obtained the data, which were evaluated jointly by the authors and the sponsor.

Additional contributions: Medical writing assistance and editorial/submission support were provided by Francesca Hemingway and Richard McDonald of Watermeadow Medical, an Ashfield company, part of UDG Healthcare plc, funded by Novo Nordisk A/S.


References

1. American Diabetes Association. Standards of medical care in diabetes – 2017. *Diabetes Care* 2017;40(Suppl. 1):S1–135.
2. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med* 2010;363:1410–1418.
3. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2015;373:232–242.
4. Bonds DE, Bergenstal RM, Buse JB, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ* 2010;340:b4909.
5. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–2559.
6. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med* 2012;367:319–328.
7. Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITON clinical studies in people with type 2 diabetes. *Diabetes Obes Metab* 2018;20:541–548.
8. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position

- statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2017;40:155–157.
9. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care* 2013;36:1384–1395.
 10. American Diabetes Association. Standards of medical care in diabetes – 2018. *Diabetes Care* 2018;41(Suppl. 1):S1–159.
 11. European Medicines Agency. Guideline on clinical investigation of medicinal products in 4 the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 2. 2018.
https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf
 12. Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. *JAMA* 2017;318:45–56.
 13. Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. *JAMA* 2017;318:33–44.
 14. Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1. *Am Heart J* 2016;179:175–183
 15. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med* 2017;377:723–732.


16. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191–2194.
17. ICH. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. *J Postgrad Med* 2001;47:199–203.
18. American Diabetes Association Workgroup on Hypoglycemia. *Diabetes Care* 2005;28:1245–1249.
19. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry - Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (draft guidance). 2008.
<https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf>.
Accessed 30 July 2018.
20. Chow E, Bernjak A, Walkinshaw E, et al. Cardiac autonomic regulation and repolarization during acute experimental hypoglycemia in type 2 diabetes. *Diabetes* 2017;66:1322–1333.
21. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarisation during insulin-induced hypoglycemia. *Diabetes* 2003;52:1469–1474.
22. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. *Diabetes* 1993;42:1233–1237.
23. Schnell O, Barnard K, Bergenstal R, et al. Role of continuous glucose monitoring in clinical trials: recommendations on reporting. *Diabetes Technol Ther* 2017;19:391–399.

Figure 1: Non-severe hypoglycemic events (total and symptomatic) in the maintenance period of SWITCH 2 and 1 at different plasma glucose levels in a pooled randomized treatment dataset



The event rates in the pooled randomized treatment dataset (degludec and glargine U100) are plotted at a given plasma glucose level or lower. PYE, patient year of exposure.

Figure 2: Estimated rate ratios of non-severe hypoglycemic events (total and symptomatic; degludec versus glargine U100) in the maintenance period of SWITCH 2 and 1 at different plasma glucose levels



The solid lines represent the estimated rate ratio (degludec versus glargine U100) at different plasma glucose levels. The dashed lines represent the upper and lower 95% confidence intervals. Glargine U100, insulin glargine 100 units/mL.

Figure 3: Proportion of non-severe hypoglycemic events that were symptomatic in SWITCH 2 at different plasma glucose levels





Figure 4: Hypoglycemic events in SWITCH 2 and DEVOTE by treatment group



^aThe total trial duration was 64 weeks; this included 32 weeks' treatment with once-daily degludec or glargine U100 followed by crossover to glargine U100 or degludec, respectively, for a further 32 weeks. Each 32-week treatment period consisted of a 16-week titration period and a 16-week maintenance period.

^bPre-specified hypoglycemia definition as used during the original SWITCH 2 and DEVOTE trials.

^cThe median observation time was 1.99 years, and the median exposure time was 1.83 years.

ADA 2005: plasma glucose ≤ 3.9 mmol/L with symptoms; IHSG Level 2: glucose < 3.0 mmol/L; IHSG Level 3: severe events requiring third-party assistance intervention independent of a defined glucose; Novo Nordisk: plasma glucose < 3.1 mmol/L with symptoms plus severe events.

Glargine U100, insulin glargine 100 units/mL.